Evidence map›Paper›PMID 36830579›Full record

ReviewBiomolecules2023

Structure-Guided Strategies of Targeted Therapies for Patients with

Zhenfang Du, Jinghan Sun, Yunkai Zhang, Nigaerayi Hesilaiti, Qi Xia, Heqing Cui, Na Fan, Xiaofang Xu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Zhenfang DuDepartment of Genetic and Developmental Biology, School of Medicine, Southeast University, Nanjing 210003, China.ORCID 0000-0001-6364-1321
Jinghan SunSchool of Life Science and Technology, Southeast University, Nanjing 210018, China.
Yunkai ZhangBioSpatula LLC, Telford, PA 18969, USA.
Nigaerayi HesilaitiDepartment of Genetic and Developmental Biology, School of Medicine, Southeast University, Nanjing 210003, China.
Qi XiaDepartment of Genetic and Developmental Biology, School of Medicine, Southeast University, Nanjing 210003, China.
Heqing CuiDepartment of Radiotherapy, Nanjing Chest Hospital, Nanjing Medical University Affiliated Brain Hospital, Nanjing 210029, China.
Na FanDepartment of Respiratory Medicine and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Xiaofang XuDepartment of Thoracic Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.
Southeast University · CNNanjing Chest Hospital · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CNZhejiang Cancer Hospital · CN

Funding

American Association For Cancer Research 18-40-12-DUFundamental Research Funds for the Central Universities 2242022R10072
6 · The paper itself

Abstract

Oncogenic mutations within the EGFR kinase domain are well-established driver mutations in non-small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) specifically targeting these mutations have improved treatment outcomes for patients with this subtype of NSCLC. The selectivity of these targeted agents is based on the location of the mutations within the exons of the

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsHumansMutationProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsEGFRnon–small cell lung cancerstructuretargeted therapy

Identifiers

PMID36830579
PMCPMC9953181
OpenAlexW4317739619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.